We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+20.86%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$710M
AUM Growth
+$164M
Cap. Flow
+$64.1M
Cap. Flow %
9.04%
Top 10 Hldgs %
36.24%
Holding
113
New
11
Increased
54
Reduced
24
Closed
24

Top Buys

Rank Stock Value
1
ABT icon
Abbott
ABT
+$15.7M
2
INSP icon
Inspire Medical Systems
INSP
+$12.4M
3
AMGN icon
Amgen
AMGN
+$11.3M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$10.7M
5
QGEN icon
Qiagen
QGEN
+$10M

Top Sells

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$13.8M
2
IMGN
Immunogen Inc
IMGN
+$11.4M
3
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$8.68M
4
CRL icon
Charles River Laboratories
CRL
+$8.65M
5
ZBH icon
Zimmer Biomet
ZBH
+$7.97M

Sector Composition

Rank Sector Weight
1 Healthcare 98.72%
2 Industrials 0.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BSX icon
1
Boston Scientific
BSX
$71.5B
$37.7M 5.32%
652,803
+55,543
+9% +$2.96M
UTHR icon
2
United Therapeutics
UTHR
$23.1B
$35.5M 5%
161,539
+23,211
+17% +$5.35M
COO icon
3
Cooper Companies
COO
$14.5B
$28.5M 4.01%
300,732
+39,448
+15% +$3.31M
DXCM icon
4
DexCom
DXCM
$32B
$28M 3.94%
225,615
-39,903
-15% -$4.08M
THC icon
5
Tenet Healthcare
THC
$21.1B
$27M 3.8%
356,806
+130,665
+58% +$8.28M
COR icon
6
Cencora
COR
$61.2B
$21.1M 2.98%
102,891
+6,046
+6% +$1.18M
INSP icon
7
Inspire Medical Systems
INSP
$1.74B
$21.1M 2.97%
103,746
+76,823
+285% +$12.4M
RXST icon
8
RxSight
RXST
$260M
$20.7M 2.91%
513,032
+131,701
+35% +$3.86M
PODD icon
9
Insulet
PODD
$9.79B
$19.2M 2.71%
88,675
+46,650
+111% +$8M
NBIX icon
10
Neurocrine Biosciences
NBIX
$16.6B
$18.5M 2.6%
140,116
+56,271
+67% +$6.48M
AMGN icon
11
Amgen
AMGN
$222B
$17.7M 2.5%
61,524
+41,524
+208% +$11.3M
ABT icon
12
Abbott
ABT
$187B
$17.3M 2.43%
+156,727
New +$15.7M
PCVX icon
13
Vaxcyte
PCVX
$8.64B
$16.8M 2.37%
267,594
+29,462
+12% +$1.53M
BDX icon
14
Becton Dickinson
BDX
$48.2B
$16.4M 2.32%
67,458
-30,494
-31% -$7.52M
SNDX icon
15
Syndax Pharmaceuticals
SNDX
$1.82B
$16M 2.25%
738,589
+526,141
+248% +$8.09M
SDGR icon
16
Schrodinger
SDGR
$1.36B
$14.5M 2.04%
405,232
+36,578
+10% +$1.06M
KROS icon
17
Keros Therapeutics
KROS
$221M
$14.3M 2.02%
360,467
+61,992
+21% +$1.94M
XENE icon
18
Xenon Pharmaceuticals
XENE
$6.12B
$13.6M 1.91%
294,788
+78,144
+36% +$2.76M
ITCI
19
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$13.3M 1.88%
+186,272
New +$10.7M
QGEN icon
20
Qiagen
QGEN
$8.72B
$10.9M 1.53%
+235,764
New +$10M
KNSA icon
21
Kiniksa Pharmaceuticals
KNSA
$5.93B
$10.8M 1.52%
615,693
+105,883
+21% +$1.74M
IONS icon
22
Ionis Pharmaceuticals
IONS
$9.4B
$10.7M 1.51%
211,400
+51,897
+33% +$2.49M
VRNA
23
DELISTED
Verona Pharma
VRNA
$10M 1.41%
504,742
+86,809
+21% +$1.28M
ACLX
24
DELISTED
Arcellx
ACLX
$9.34M 1.32%
168,262
-35,220
-17% -$1.59M
TVTX icon
25
Travere Therapeutics
TVTX
$5.78B
$9.16M 1.29%
1,018,812
+441,318
+76% +$3.21M
1
2 3 4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
SFO
Stokes Family Office New Orleans, Louisiana $969M AUM 19.6% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return

Parkman Healthcare Partners's Q4 2023 Portfolio in Review

As of Q4 2023, Parkman Healthcare Partners held 113 positions worth $710M, up 30% from $546M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Parkman Healthcare Partners deployed $64.1M of net new capital in Q4 2023, opening 11 new positions and adding to 54 existing holdings. Its largest new stake was Abbott: 156,727 shares worth $17.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Becton Dickinson, an estimated $7.52M trimmed.

  • Parkman Healthcare Partners's largest Q4 2023 buy was Abbott: 156,727 shares worth $17.3M.
  • Parkman Healthcare Partners added most to Inspire Medical Systems in Q4 2023, an estimated $12.4M increase.
  • Parkman Healthcare Partners's biggest Q4 2023 reduction was Becton Dickinson, cutting an estimated $7.52M.
  • Parkman Healthcare Partners fully exited HCA Healthcare in Q4 2023, selling an estimated $13.8M.
  • Parkman Healthcare Partners's ten largest holdings make up 36% of its $710M portfolio in Q4 2023.
  • Parkman Healthcare Partners opened 11 new positions and closed 24 in Q4 2023.
  • Parkman Healthcare Partners's portfolio value rose 30% quarter-over-quarter to $710M.

Based on Parkman Healthcare Partners's 13F filing for Q4 2023, filed 14 Feb 2024.